Dr. Jed Pollack, MD
Claim this profileLenox Hill Brain Tumor Center
Studies Glioblastoma
Studies Brain Tumor
3 reported clinical trials
4 drugs studied
Affiliated Hospitals
Clinical Trials Jed Pollack, MD is currently running
Cetuximab + Reirradiation
for Brain Cancer
Primary brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the low 5-year survival rate for brain cancer patients, with median survival at approximately 12 months. Glioma is the most common form of primary brain cancer, afflicting approximately 7,000 patients in the United States each year. These highly malignant cancers remain a significant unmet clinical need in oncology. GBM often has a high expression of EFGR (Epidermal Growth Factor Receptor), which is associated with poor prognosis. Several methods of inhibiting this receptor have been tested, including monoclonal antibodies, vaccines, and tyrosine kinase inhibitors. The investigators hypothesize that in patients with recurring GBM, intracranial superselective intra-arterial infusion of Cetuximab (CTX), at a dose of 250mg/m2 in conjunction with hypofractionated radiation, will be safe and efficacious and prevent tumor progression in patients with recurrent, residual GBM.
Recruiting3 awards Phase 21 criteria
Intra-arterial Cetuximab
for Newly Diagnosed Glioblastoma
Primary brain cancer kills up to 10,000 Americans a year. These brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the low 5-year survival rate for brain cancer patients, with median survival at approximately 12 months. Glioma is the most common form of primary brain cancer, afflicting approximately 7,000 patients in the United States each year. These highly malignant cancers remain a significant unmet clinical need in oncology. GBM often has a high expression EFGR (Epidermal Growth Factor Receptor) which is blocked by Cetuximab (CTX). The investigators have recently completed a separate Phase I clinical trial using superselective intra-arterial cerebral infusion (SIACI) of CTX after blood brain barrier disruption (BBBD) for recurrent GBM (Chakraborty et al, in revision, Journal of Neurooncology). The investigators found that intra-arterial infusion of CTX is well tolerated with few adverse effects. The investigators hypothesize that in patients with newly diagnosed GBM, repeated SIACI of this drug after BBBD will be safe and efficacious for our patients when combined with standard chemoradiation (STUPP protocol). This trial will be a non-randomized open label Phase I/II clinical trial. In addition to standard chemotherapy and radiation therapy (STUPP protocol) the patient will be given CTX intra-arterially after BBBD for a total of three doses at approximately post surgery days 30, 120 and 210.
Recruiting3 awards Phase 1 & 2
More about Jed Pollack, MD
Clinical Trial Related10 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Jed Pollack, MD has experience with
- Cetuximab
- Cetuximab (Erbitux)
- Hypofractionated Re-irradiation
- Mannitol
Breakdown of trials Jed Pollack, MD has run
Glioblastoma
Brain Tumor
Uterine Tumors
Brain Metastases
Brain Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Jed Pollack, MD specialize in?
Is Jed Pollack, MD currently recruiting for clinical trials?
Are there any treatments that Jed Pollack, MD has studied deeply?
What is the best way to schedule an appointment with Jed Pollack, MD?
What is the office address of Jed Pollack, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.